Repligen record Q3, ups 2026 guidance, sees 2027 >$1B revenue with BioLife acquisition

 

• Record Q3 2026 revenue $209.3M, up 11% YoY, 12.5% organic growth, again outpacing the still-recovering bioprocessing market.
• Fiscal Q3 2026 adjusted non-GAAP EPS $0.53, up 15% YoY; adjusted operating margin 15.9% (+170 bps); gross margin 53%.
• Chromatography, proteins and analytics grew >50%, >40%, 20%, driving higher 2026 revenue and EPS guidance.
• Filtration down 11% and capital equipment revenue soft; rebound largely deferred into 2027.
• 2026 guidance raised after Q3 beat, complementing new 2027 framework: revenue $844–852m, organic growth 12–13%, EPS $2.05–2.09, margin expansion.
• 2027 framework with BioLife targets at least 25% reported growth and revenue surpassing $1 billion.
• Growth drivers: consumables and services >20%, China >40%, cell therapy ~30%, gene therapy >25%.
• 2026 operating margin guided to 16–16.3% (+220–250 bps); BioLife margin-accretive and accretive despite near-term EPS dilution.
• Notable items: $41m non-cash IP impairment, Polymem divestiture, strong cash balance >$300m post-BioLife.
• Q&A focus: BioLife synergies, capital equipment backlog conversion, filtration/ATF recovery, onshoring projects, biosimilar-driven ATF demand.
• Main concern: Timing and magnitude of capital equipment recovery and filtration rebound remain uncertain heading into 2027.
• Strong quarter, BioLife acquisition closed alongside Q3 2026 results, broad-based consumables and services growth, margin-accretive BioLife contribution.

https://finviz.com/stock?t=RGEN&p=d